CD274 and cancer: Immune checkpoint therapy blocking PD-1, PD-L1, and/or CTLA-4 has proven to be successful in several cancer types, usually characterized by high mutation burdens and a relatively dense T-cell infiltrate, such as melanoma or non-small-cell lung cancer (NSCLC) [167,168].